News & Announcements
Gates Foundation Funds UMass Amherst Research on Deadly African Cattle Disease
Gates Foundation Funds UMass Amherst Research on Deadly African Cattle Disease
Samuel Black (Department of Veterinary and Animal Sciences), a researcher in the Molecular and Cellular Biology (MCB) Program, along with collaborators elsewhere in the United States and Europe, has been awarded a $478,000 grant to develop a vaccine against trypanosomes, protozoan parasites that cause trypanosomiasis. The disease, fatal to cattle in sub-Saharan Africa, is a major obstacle to raising livestock in the region. Other researchers funded by the grant will focus on furthering the use of trypanosome variable surface glycoprotein (VSG) for these immunizations, while Black’s work will determine if immunization with other conserved trypanosome membrane proteins, possibly in concert with VSG, will have a positive impact on disease control.
UMass Amherst Chemist Receives $6.25 Million Grant to Develop Molecular Signals
UMass Amherst Chemist Receives $6.25 Million Grant to Develop Molecular Signals
Researchers in the Molecular and Cellular Biology (MCB) Program, Sankaran Thayumanavan (Chemistry Department) and Jennifer Ross (Physics Department) in collaboration with a team of chemists, physicists and chemical engineers have been awarded a $6.25 million grant to study molecular pathways and signaling processes. The U.S. Department of Defense (DoD) is funding the interdisciplinary team of researchers to develop new algorithms and as Thaymanavan explains "If we can develop the fundamental science that provides pathways for detecting a variety of molecules around us, then the impact will be huge. Developing the science to seamlessly connect molecular-scale events with macroscopically discernible processes is the focus of this MURI team."
MCB Students Receive Fellowships
MCB Students Receive Fellowships
Safia Omer, 4th year student in Wei-Lih Lee’s lab in the Biology Department and Cameron Butova, 2nd year student in Scott Garman’s lab in the Biochemistry and Molecular Biology Department have both been awarded fellowships from the Biotech Training Program (BTP) for the following two years. The BTP training program is newly established through a T23 grant. Students granted this fellowship will complete BTP curriculum, complete an Individual Development Plan (IDP) with the Office of Professional Development, and pursue an Industrial Internship in addition to ongoing research in their labs.
How Biotechnology Innovations are Transforming Pharmaceutical Research
How Biotechnology Innovations are Transforming Pharmaceutical Research
Special MCB Colloquium in Collaboration with the Office of Professional Development
Monday, November 30th - 12:00pm-1:15pm
1634 Lederle Graduate Research Tower (LGRT)
Alexion Pharmaceuticals is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Dr. Michael Perricone, Exec. Dir., Global Research Strategy & Operations, will discuss the launch of a new laboratory focused on network medicine to advance Alexion’s mission. He will share insights about the science behind the initiative and describe how other innovation initiatives are poised to disrupt traditional drug development processes and deliver more drugs to patients. Co-sponsored with the Molecular and Cellular Biology Graduate Program.
New Protein Cleanup Factors Found to Control Bacterial Growth
New Protein Cleanup Factors Found to Control Bacterial Growth
Researchers in Peter Chien's lab in the department of biochemistry and molecular biology at the University of Massachusetts Amherst report finding how an essential bacterial protease controls cell growth and division. Details appear in the journal CELL. Lead author Kamal Joshi, a doctoral candidate in the Chien lab, conducted experiments in the model bacterium Caulobacter crescentus. In this species, the ability to grow and replicate DNA is regulated by ClpXP, a highly conserved protease that in many bacteria allows them to cope with stressful environments such as the human body. Understanding how ClpXP is controlled could open a path to antibiotics that inhibit harmful bacteria in new ways.
